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Trigeminal neuronDREAM is a Ca2+-binding protein with speciﬁc functions in different cell compartments. In the nucleus,
DREAM acts as a transcriptional repressor, although the mechanism that controls its nuclear localization is
unknown. Yeast two-hybrid assay revealed the interaction between DREAM and the SUMO-conjugating
enzyme Ubc9 and bioinformatic analysis identiﬁed four sumoylation-susceptible sites in the DREAM
sequence. Single K-to-R mutations at positions K26 and K90 prevented in vitro sumoylation of recombinant
DREAM. DREAM sumoylation mutants retained the ability to bind to the DRE sequence but showed reduced
nuclear localization and failed to regulate DRE-dependent transcription. In PC12 cells, sumoylated DREAM is
present exclusively in the nucleus and neuronal differentiation induced nuclear accumulation of sumoylated
DREAM. In fully differentiated trigeminal neurons, DREAM and SUMO-1 colocalized in nuclear domains
associated with transcription. Our results show that sumoylation regulates the nuclear localization of DREAM
in differentiated neurons. This article is part of a Special Issue entitled: 11th European Symposium on Calcium.ement antagonist modulator;
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Sumoylation is a post-translational modiﬁcation with critical
effects on protein function through the control of protein interactions,
subcellular localization, and stability/degradation [1]. Sumoylation has
an important role in the nuclear import of several transcription factors,
e.g., CREB and STAT [2,3] or in the nuclear-cytosolic shuttling of Elk-1
[4], regulating their function in gene expression. The sumoylation
process involves the sequential action of a small ubiquitin-like
modiﬁer (SUMO), an E1-activating enzyme (SAE1/SAE2), an E2-
conjugating enzyme (Ubc9), and usually an E3 SUMO protein ligase.
Ubc9 recognizes substrate proteins directly and, often in conjunction
with an E3 ligase, catalyzes the transfer of SUMO to the sumoylation
motif in the target protein [5]. Sumoylation sites having the strict
consensus sequence YKxE (where Y is a bulky, hydrophobic residue,
typically Ile, Leu, or Val [2,6]) occur in many target proteins, although
non-consensus sequences may as well be sumoylated [2,7]. The
simultaneous occurrence of another post-translational modiﬁcation,
e.g., phosphorylation, can alsomodify the sumoylation process [8]. Thestructural context of the sumoylation process is not yet fully
understood, but it is safe to assume that Lys residues that are not
surface-exposed will not qualify for sumoylation [1]. Thus, a sumoyla-
tion site is necessary, but not sufﬁcient, for sumoylation to take place.
DREAM, alsoknownas calsenilin orKChIP3, is amemberof theKChIP
family of structurally and functionally relatedproteins found indifferent
cell compartments, with speciﬁc activities in each. In the nucleus,
DREAM is a Ca2+-sensitive transcriptional repressor that binds to DNA
and interacts with other nucleoproteins to regulate expression of
several genes, including prodynorphin [9–11]. Outside the nucleus,
DREAM interacts with presenilins to regulate APP processing [12] and
with Kv4 potassium channels to regulate their membrane expression
and gating [13,14]. DREAM localization in the cytosol and the nucleus
has been described in basal conditions for primary cultured neurons and
most cell lines [15,16]. Nuclear translocalization of DREAM is triggered
by serum deprivation in human H4 neuroglioma cells, whereas nuclear
export is induced by Ca2+ ionophore [17]. The molecular mechanisms
that mediate nuclear import of DREAM are presently unknown, and no
recognizable nuclear localization signals have been found in theDREAM
protein (LOCtree http://www.psort.org/).2. Materials and methods
2.1. Animals
Experiments involving the use of animals were conducted in
accordance with the standard ethical guidelines (European Communities
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the local ethical committees (CNB and UC).
2.2. Plasmids
Eukaryotic and prokaryotic expression vectors for DREAMhave been
described [9]. DREAM was subcloned in the Myc-tagged pCS2+M
vector. The Ca2+-insensitive DREAM mutant (EFmDREAM), wild-type
DREAM, and antisense DREAM (AS-DREAM) were subcloned in pAS2-1
[14]. Reporter plasmid pGL2-NCX3 [16]was used in the luciferase assay.
The EGFP-SUMO and EGFP-SUMOΔ6 plasmids (gift from C. Santoro,
Novara, Italy) and the Ubc9 plasmid (gift from R. Hay, St Andrews,
Scotland) were previously described [5,18]. SUMO and Ubc9 were
subcloned in HA-tagged pcDNA3 and Ubc9 in pACT2. The DREAM
mutants K26R, K90R, K101R, K241, and K26,90R were prepared in the
eukaryotic and prokaryotic expression constructs using the Quick-
Change method (Stratagene). Wild-type DREAM and sumoylation
mutants were subcloned in pEGFP-C1 (Clontech).
2.3. Direct yeast two-hybrid assay
The yeast strain Saccharomyces cerevisiae AH109 (Clontech) was
used. Yeast were cotransformed with the bait (pAS2-1-EFmDREAM or
pAS2-1-DREAM) and target (pACT2-Ubc9) plasmids. Cotransformants
were selected by plating on selective media SDDDO and SDQDO
(Clontech Matchmaker protocol handbook). Cotransformation of the
bait pAS2-1-antisense-DREAM with target vector pACT2-Ubc9 was
used as negative control for the interaction.
2.4. Cell culture, transfection, and transduction with lentiviral vectors
HEK 293 and HeLa cells were cultured in Dulbecco's modiﬁed
Eagle's medium with 10% fetal bovine serum. Cells were transfected
using Jet/PEI reagent (Poly+ Transfection), according to the manufac-
turer's instructions. Primary cortico-hippocampal neurons from
DREAM−/− mouse E14 embryos were cultured and 2 days later
exposed to lentiviral particles (5 μg of p24/106 cells) as described [16].
The medium was changed 8 h after addition of the virus, and cells
were harvested after 7 days. Infection efﬁciency was typically 90% as
assessed using viral delivery of GFP. PC12 cells and PC12 subline UR61
were grown in Dulbecco's modiﬁed Eagle's medium with 10% fetal
bovine serum, 5% horse serum. Neuronal differentiation was induced
by exposure to dexamethasone as described [19] or by addition of NGF
(25 ng/ml) to the culture medium.
2.5. Immunoprecipitation and Western blot
Whole cell extracts were prepared by incubation on ice for 30 min
with lysis buffer [20 mM Hepes, pH7.5; 100 mM KCl, 1 mM EDTA; 1%
NP40] supplemented with protease inhibitor cocktail (Roche) and
25 mM NEN (Sigma) for prevention of desumoylation. Cytosolic and
nuclear extracts were prepared as described [20] and in the presence
of 25 mMNEN. Coimmunoprecipitation of DREAM and Ubc9was done
with whole cell extracts (300 μg) from HEK293 cells overexpressing
Myc- and HA-tagged proteins, respectively. Antibodies used were
anti-Myc (9E10, St. Cruz and ab9106, Abcam) and anti-HA (715500,
Zymed and F-7, St. Cruz). For coimmunoprecipitation of DREAM and
SUMO-1, cytosolic or nuclear extracts (450 μg) from PC12 cells were
incubated with 1 μg of a DREAM-speciﬁc afﬁnity-puriﬁed rabbit
polyclonal antibody (Ab1014) [21]. Western blot was with mouse
monoclonal anti-SUMO-1 (21C7, Zymed). Proteins were visualized
with HRP-conjugated secondary antibody (Jackson) followed by ECL
(West Dura, Pierce). Blots were quantiﬁed using the Quantity One
software (BioRad).2.6. Sumoylation assay
Histidin-tagged proteins were expressed and puriﬁed according to
standard protocols. The puriﬁed proteins were dialyzed against
sumoylation buffer (20 mM Hepes, pH 7.5, 5 mM MgCl2). For the in
vitro sumoylation assay, the K007 kit (LEA Biotech International) was
used according to the manufacturer's protocol. Protein sumoylation
was analyzed by SDS-PAGE and Western blotting using anti-DREAM
(Ab1014) [21]and anti-SUMO-1 (21 C7, Zymed).2.7. Luciferase reporter and electrophoretic mobility shift assays
The luciferase reporter assay was performed as described [16]
using a luciferase reporter driven by the NCX3 promoter. EMSA
experiments were performed as described [9], using a labeled double-
stranded oligonucleotide corresponding to the human prodynorphin
DRE site and with 5 μg protein extracts from HEK 293 cells transfected
with DREAM, wild-type, or sumoylation mutants.2.8. Immunoﬂuorescence and confocal microscopy
HeLa cells were transfected with wild-type DREAM or DREAM
sumoylation mutants and EGFP-SUMO. After 24 h, cells were ﬁxed
with 4% formaldehyde for 30 min, washed 3 times with PBS, and
permeabilized with 2% Triton X-100. Blocking was performed by
incubation in 10% FBS in PBS for 60 min, after which the cells were
incubated with anti-DREAM antibody (Ab1014) [21] and visualized
with anti-rabbit secondary antibody Alexa 594 (1:500, Invitrogen).
Microscopy was performed with a Radiance 2100 (Bio-Rad) Laser
Scanning System on a Zeiss Axiovert 200 microscope. The images
were sequentially taken using LaserSharp v5.0 software (Bio-Rad) and
analyzed using LaserPix v.4 image software (Bio-Rad). The laser lines
employed were the appropriate for the different ﬂuorophore
excitation. Individual channels were overlaid using Image J software,
and colocalization was determined using the Image J RG2B colocaliza-
tion plug-in.
For preparation of freshly dissociated sensory neurons, rats were
perfused with 3.7% paraformaldehyde. Sensory neurons were disso-
ciated from tissue fragments of trigeminal ganglia and processed for
immunoﬂuorescence as previously described [22]. The following
primary antibodies were used: rabbit polyclonal anti-DREAM
(Ab1014) [21], mouse monoclonal anti-panHistone (Roche), mouse
monoclonal anti-U2B″ (4G3, Euro Diagnostica) that recognizes the
spliceosomal U2B″ small nuclear ribonucleoprotein (snRNP), and
mouse monoclonal anti-SUMO-1 (21C7, Zymed).2.9. Electron microscopy immunocytochemistry
For immunoelectron microscopy, rats were ﬁxed with 4%
paraformaldehyde in 0.12 M phosphate buffer, pH 7.4. Small frag-
ments of trigeminal ganglia were dehydrated in methanol and
embedded in Lowicryl K4M at −20 °C. Ultrathin sections were
mounted on nickel grids and sequentially incubated with 0.1 M
glycine in PBS for 15 min, with normal goat serum diluted 1:100 in
PBS for 3 min and with rabbit polyclonal anti-DREAM antibody
(Ab1014) [21], diluted in PBS containing 0.1 M glycine and 1% BSA, for
1 h at room temperature. After washing, the sections were incubated
with goat anti-rabbit secondary antibody conjugated to 10-nm gold-
particles (BioCell, UK) diluted 1:25 in 1% BSA in PBS for 45 min at
room temperature. Sections were stainedwith uranyl acetate and lead
citrate and examined with a Philips EM-208 electron microscope. As
controls, ultrathin sections were treated as described above omitting
the primary antibody.
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RNA from primary neurons was prepared as described [16].
Quantitative real-time PCR for prodynorphin and c-fos was performed
using speciﬁc kits from Applied Biosystems. The results were
normalized by quantiﬁcation of HPRT mRNA using the speciﬁc
primers; forward 5′-TTGGATACAGGCCAGACTTTGTT-3′ and reverse
5′-CTGAAGTACTCAT TATAGTCAAGGGCATA-3′, and the probe FAM-5′-
TTGAAATTCCAGACAAGTTT-3′-MGB.Fig. 1. DREAM interacts with Ubc9. (A) Direct yeast two-hybrid assay using EFmDREAM2.11. Bioinformatics analysis
To detect suitable templates for structural modeling, the DREAM
protein was used as a query for the BLAST tool [23] against the
structural databases. As structural templates were found, a careful,
manually curated pairwise alignment was generated for each
template. We further conducted homology modeling using the best
alignments in terms of coverage and identity using the WHATIF [24]
and SWISS-MODEL [25] servers. The models were evaluated using the
WHATIF server and further visualized with pymol (http://pymol.
sourceforge.net/). Secondary structure predictions were conducted in
regions not covered by the template using JPRED (http://www.
compbio.dundee.ac.uk/~www-jpred/). Accessibility values that report
residues that are solvent-exposed were calculated on the model and
the template using the DSSP suite [26].or wild-type DREAM as baits and Ubc9 as the target. DDO is nonselective and QDO is
selective plating medium. Cotransformation of antisense DREAM (AS-DREAM) with
Ubc9 was used as negative control. (B) Coimmunoprecipitation of DREAM-Myc and
Ubc9-HA after overexpression in HEK 293 cells. Empty vectors or expression plasmids
used are indicated below. Incubation without antibody was used as negative control
and is shown in the last lane (−Ab).3. Results
3.1. DREAM interacts with the SUMO-conjugating enzyme Ubc9
To identify new protein–protein interactions that could reveal
DREAM functions in the cell, we previously screened a pre-transformed
human brain library using the yeast two-hybrid assay and a Ca2+-
insensitiveDREAMmutant (EFmDREAM)as thebait [14].One interaction
corresponding to a clone encoding Ubc9, a key enzyme for sumoylation
[5], was further studied. Direct yeast two-hybrid assay conﬁrmed the
interaction and showed that wild-type DREAM also interacts with Ubc9
(Fig. 1A), suggesting that the interaction is not Ca2+-sensitive. To conﬁrm
the interaction in mammalian cells, we coimmunoprecipitated Ubc9-HA
and DREAM-Myc after overexpression in HEK 293 cells, a cell line that
does not express endogenous DREAM and shows good transfection
efﬁciency.Western blots showed a 37- and a23-kDaband corresponding
to DREAM-Myc and Ubc9-HA, respectively (Fig. 1B), conﬁrming DREAM
as a potential sumoylation target.Table 1
Putative sumoylation sites in the DREAM sequence.
A
No. Positiona Group Score
1 K101 SLYRG FKNE CPTGL 0.85b
2 K241 FLEAC QKDE NIMSS 0.50
3 K221 VERFF EKMD RNQDG 0.50
4 K27 HTPLS KKEG IKWQR 0.31
B
Positionc Flanking peptide GPS score Cutoff Site type
26d LGHTKF TKKE GIKWQ 2.618 2.260 Non-consensus
90 QAQTKF TKKE LQSLY 3.647 2.260 Non-consensus
101 QSLYRG FKNE CPTGL 0.635 0.100 Ψ–K–X–E
184 NKDGYI TKEE MLAIM 2.985 2.260 Non-consensus
241 EFLEAC QKDE NIMSS 2.618 2.260 Non-consensus
a SUMOplot (http://www.abgent.com/tool/sumoplot/).
b Sites found using SUMOplot (A) are listed in decreasing probability order (score 1
equals perfect site).
c SUMOsp 1.0 (http://bioinformatics.lcd-ustc.org/sumosp/).
d SUMOsp sites (B) are listed by position.3.2. DREAM has six potential sumoylation sites
Since DREAM is a potential target for sumoylation, we searched for
putative sumoylation sites within DREAM. SUMOplot (http://www.
abgent.com/tool/sumoplot) and SUMOsp 2.0 (http://bioinformatics.
lcd-ustc.org/sumosp/ [7]) predicted four sites at K26/K27, K101, K184,
and K241, whereas sites at K221 and K90were detected only either by
SUMOplot or by SUMOsp, respectively (Table 1). K101 falls within a
strict consensus YKxE sumoylation sequence (FKNE), while the other
ﬁve lysines (K26/27, K90, K184, K221, and K241) are within weak
consensus KxE/D sequences (Fig. 2). Homologymodeling based on the
crystal structure of KChIP-1 [27] and predictions from the NMR
structure of DREAM [28] indicated that K90, K101, and K241 are
surface-exposed, while the sites centered at K184 and K221 are less
exposed (Table 2). Surface exposure of K26/27 could not be judged
because the N-terminal region is highly variable among the KChIP
family members and is not resolved in any of the structures available
for these proteins.3.3. DREAM is sumoylated in vitro at multiple sites
To validate the in silico predictions, we analyzed DREAM sumoyla-
tion in vitro. Puriﬁed recombinant DREAM showed two bands in
Western blot, a major 29-kDamonomeric form and a minor oligomeric
formmigrating at 60 kDa (Fig. 3A). After in vitro sumoylation, we found
an additional DREAM-immunoreactive doublet migrating at 40 kDa
(Fig. 3A, lane 6). Of note, this doublet was detected only when all
components required for in vitro sumoylation were present in the
reaction (Fig. 3A, lane 6) indicating that the 40-kDa band corresponds to
sumoylated monomeric DREAM.
Fig. 2. Sequence alignment of DREAM/KChIP family members. Potential sumoylation sites are labeled in blue. Serine residues at position +5 from the key lysine residue in
sumoylation sites are labeled in red. The human sequences for DREAM (Acc. Q9Y2W7), KChIP 1 (Q9NZI2), KChIP 2 (Q9NS61), and KChIP 4 (Q6PIL6) were aligned using the T-Coffee
program [40]. Asterisk (*) denotes identical residue; colon (:), conservative change; period (.), related substitution.
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by SUMO, K-to-R mutations were screened by in vitro sumoylation
assay. Directed by the in silico analysis, we prepared four single DREAM
mutants, K26R, K90R, K101R, and K241R. Of these, K101R showed the
same in vitro sumoylation pattern aswild-typeDREAM(Fig. 3B). For the
K26R and K90R mutants, the upper band of the 40-kDa doublet was
absent in both cases,whereas for K241R, this bandwasweaker (Fig. 3B).
The double DREAMmutant K26,90R conﬁrmed the pattern observed for
the singlemutants (Fig. 3B). These results suggest that residues K26 and
K90 are modiﬁed by SUMO in vitro, whereas residue K101 is not.
Mutationof K241 altered the sumoylation to someextent. Persistence of
the lower band in the doublet after in vitro sumoylation of K26R, K90R,
and the double K26,90R mutants suggests additional sumoylation
events within the DREAM protein that are not affected by any of these
mutations.
3.4. DREAM sumoylation mutants do not translocate to the nucleus
To determinewhether sumoylation of DREAM regulates its nuclear
translocation/retention, we cotransfected HeLa cells with DREAM and
GFP-SUMO or GFP-SUMOΔ6 and visualized the proteins by confocalTable 2
Potential sumoylation sites in the DREAM sequence.
Amino acid Homology model NMR structure
K90 103a 135
K101 87 100
K184 101 79
K241 165 149
E92 55 70
E103 123 79
E186 20 28
E223 19 20
E243 152 166
a Degree of surface exposure of K and E/D residues for the potential sumoylation sites
are shown as solvent accessibility values, representing the water-exposed residue
surface in Angstroms. Values N50 are generally accepted as exposed, whereas lower
values are considered buried.microscopy after immunostaining of DREAM. HeLa cells were used in
these experiments because they do not express endogenous DREAM.
GFP-SUMOΔ6 is a sumoylation-deﬁcient mutant that is unable toFig. 3. In vitro sumoylation of DREAM and mutation analysis. (A) Western blot with
anti-DREAM showing in vitro sumoylation of recombinant DREAM by reconstituted
SUMO complex (lane 6). In vitro sumoylated DREAM migrates as a 40-kDa doublet
(open arrowhead). Absence of E1, E2, SUMO, or all three preclude sumoylation of
DREAM (lanes 1–5). Nonsumoylated recombinant DREAM migrates as a 29-kDa
monomer and a 60-kDa dimer (ﬁlled arrowheads). (B) Western blot with anti-DREAM
showing reduced in vitro sumoylation of K26R, K90R, K26,90R, and K241R DREAM
mutants. Mutation of lysine 101 shows the same sumoylation pattern as wild-type
DREAM. Quantiﬁcation of the upper band in the doublet is shown below each lane as
ratio of band intensity relative to wild-type DREAM. Arrowheads as in panel A.
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cotransfected with GFP-SUMO, DREAM immunoreactivity localized
both in the cytosol and in the nucleus. In the nucleus, DREAM
colocalizedwith the green ﬂuorescent signal for the GFP-SUMO fusion
protein (Fig. 4, upper row). In contrast, after cotransfection with GFP-
SUMOΔ6, DREAM was largely excluded from the nucleus (Fig. 4,
bottom row). These results suggest that sumoylation is a prerequisite
for the presence of DREAM in the nucleus of HeLa cells. Cotransfection
of DREAM K26R and K90R sumoylation mutants with GFP-SUMOFig. 4. Sumoylated DREAM is located in the nucleus. Confocal microscopy of HeLa cells cotran
and DREAM mutants were visualized after immunostaining with anti-DREAM (red ﬂuores
proteins (green ﬂuorescent signal, right column). Merge is shown in the right column. Scalresulted in predominantly cytosolic localization (Fig. 4, middle rows),
conﬁrming the in vitro sumoylation results. The residual and weak
nuclear signal still visible after overexpression of DREAM K26R and
K90R sumoylation mutants could be related to the overexpression
itself or could reﬂect the existence of additional weak sumoylation
sites or alternative mechanisms for DREAM nuclear shufﬂing.
Furthermore, overexpression of DREAM K241R mutant showed both
cytosolic and nuclear localization similar to wild type (Fig. 4, middle
rows, bottom). This suggest that sumoylation at K241 either does notsfected with wild-type (wt) DREAM and GFP-SUMO and the indicated mutants. DREAM
cent signal, left column). GFP-SUMO and GFP-SUMOΔ6 were visualized as GFP-fusion
e bar corresponds to 5 μm.
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These results suggest that K26 and K90 are important residues for
DREAM sumoylation and strengthen the idea that sumoylation
regulates the nuclear localization of DREAM.
To further substantiate the relationship between sumoylation and
nuclear translocation of DREAM, we assayed the sumoylation mutants
for their capability to repress transcription. For this, ﬁrst we used a
luciferase reporter assay in HEK 293 cells devoid of endogenous
DREAM. Single K26R, K90R, and double K26,90R DREAM sumoylation
mutants showed reduced repressor activity on the NCX3 reporter
compared to wild-type DREAM or the K241R and K101R DREAM
mutants (Fig. 5A). Second, we used primary cultures of cortico-
hippocampal neurons from DREAM null embryos and quantiﬁed the
effect of wild-type or sumoylation mutant DREAM overexpression on
endogenous levels of prodynorphin and c-fos, two established DREAM
target genes in neurons [9]. Overexpression of wild-type DREAM, but
not the double K26,90R DREAM sumoylation mutant, signiﬁcantly
reduced basal expression of these two target genes (Fig. 5B). The
limited reduction (25%) of prodynorphin and c-fos mRNA levels after
DREAM over-expression in DREAM null cultured neurons is related to
the endogenous expression of other KChIP family members (Fig. 5B).
These results suggest that in both HEK 293 cells and primary neurons,
DREAM sumoylation is associated with the nuclear location needed
for transcriptional repressor activity.
To ensure that the lack of repressor activity of DREAM sumoylation
mutants is not due to reduced interaction with DNA, we performed
electrophoreticmobility shift assays usinga labeledDREoligonucleotideFig. 5. DREAM sumoylation mutants are not repressors in vivo but bind to DNA in vitro.
(A) Luciferase reporter assay with pGL2-NCX3 and DREAM or the indicated sumoylation
mutants after transient transfection inHEK 293 cells. The results are shown as themean±
SD of three independent experiments in triplicate. The K26R, K90R and K26,90R mutants
show impaired repressor activity compared to wild-type (wt) DREAM (one-way ANOVA,
Pb0.05 with Dunnett's post test). (B) Quantitative RT-PCR analysis of endogenous c-fos
and prodynorphin expression in primary cortico-hippocampal cultures of DREAM null
neurons after infection with lentiviral vectors overexpressing wild-type (wt) DREAM or
the double K26,90R mutant. Infection with a lentiviral vector encoding GFP was used as
control. The results are shown as the mean ± SD of three independent experiments in
triplicate. The K26,90R mutant does not modify endogenous expression of c-fos or
prodynorphin, while the effect of wild-type DREAM is statistically signiﬁcant compared to
control (*Pb0.05, two-tailed, unpaired t-test) or to doubleK26,90Rmutant (#Pb0.05, two-
tailed, unpaired t-test). (C) Electrophoreticmobility shift assaywithwild-type andmutant
DREAM proteins expressed in HEK 293 cells and a labeled DRE probe. Wild-type and
mutant proteins showed the same mobility shift pattern. Competition with excess
unlabeled Sp1 (cSp1) or DRE (cDRE) is shown.derived from the prodynorphin gene. The result showed that all K-to-R
mutants conserved the in vitro DNA-binding property of wild-type
DREAM (Fig. 5C).
3.5. DREAM is sumoylated in vivo and accumulates in the nucleus during
PC12 neuronal differentiation
Undifferentiated PC12 cells, which express large amounts of DREAM
[29], can be induced to attain a neuron-like phenotype by exposure to
NGF and activation of Ras signaling, by chronic depolarization, or by
increase in cAMP levels [30]. Therefore, we choose the PC12 cell system
to investigate DREAM in vivo sumoylation in basal conditions and
during neuronal differentiation. In the UR61 subline of PC12 cells
exposure to dexamethasone induces N-ras expression and neuronal
differentiation [19,31]. Differentiation of PC12 UR61 was characterized
by an increase in cell size, neurite outgrowth, and increased nuclear
accumulation of endogenous DREAM immunoreactivity (Fig. 6A).
Coimmunoprecipitation of DREAM and SUMO-1 showed that sumoy-
lated DREAM is present exclusively in the nucleus of undifferentiated
PC12 cells and that the nuclear levels are increased after NGF-induced
differentiation (Fig. 6B andC). SumoylatedDREAMmigrates as a bandof
approximately 80 kDa, corresponding to a dimer of sumoylated DREAM
(Fig. 6B). Thus, nuclear sumoylated DREAM in PC12 cells corresponds to
multimeric DREAM, the formwith highest afﬁnity for speciﬁc binding to
DRE sites in the DNA [32]. NonsumoylatedDREAM is present in both the
cytosol and nucleus as a monomer (Fig. 6B). Following NGF-induced
differentiation, monomeric DREAM also accumulates in the nuclear
compartment, while it is less abundant in the cytosol (Fig. 6B and C).
These results suggest that nuclear translocation/retention of DREAM is
enhanced after neuronal differentiation in PC12 cells and that
sumoylated DREAM is present exclusively in the nucleus.
3.6. DREAM and SUMO-1 colocalize in the nucleus in trigeminal neurons
Neurons involved in sensory processing express high levels of
DREAM [33]. In sensory neurons from the trigeminal ganglia, we found
that DREAM immunoreactivity is diffuse in the cytoplasm and
concentrated in the nucleus, excluding the nucleolus (Fig. 7A). Double
immunolabeling of DREAM and pan-histone, a chromatin marker,
demonstrated colocalization in chromatin domains (Fig. 7A–C), while
costaining with spliceosomal snRNP showed that DREAM did not
colocalize with splicing factors in nuclear speckles or Cajal bodies
(Fig. 7D–F, arrowhead), nuclear compartments in which snRNP is
concentrated and where no transcription takes place [34,35]. Impor-
tantly, coimmunolabeling for DREAM and SUMO-1 demonstrated the
nuclear colocalization of both molecular components (Fig. 7G–I and
inset). The slight increase of signal intensity of SUMO-1 at the nuclear
periphery (Fig. 7I) is consistent with the sumoylation of RanGAP1 at the
nuclear pore complex, a modiﬁcation associated with nucleo-cytoplas-
mic trafﬁc regulation [36]. The nuclear distribution of DREAM was
further analyzed using immunogold electronmicroscopy. Gold particles
of DREAM immunoreactivity appeared in domains of decondensed
chromatin (euchromatin) and were conspicuously absent in both
nucleolus and Cajal bodies (Fig. 8A and B). Interestingly, tangential
sectionsof thenuclear envelope illustrated thepresence of goldparticles
directly associated with the rings of the nuclear pore complex (Fig. 8C)
supporting the nuclear trafﬁc of DREAM and the results from the
colocalization analysis (see Fig. 7G–I).
4. Discussion
Transcriptional repressor activity of DREAM is regulated by its Ca2+-
dependent interaction with DRE sites in the DNA. Importantly, the
sumoylation-dependent nuclear translocalization of DREAM identiﬁed
in this study represents a novel mechanism to further regulate the
repressor activity of DREAM.
Fig. 6. DREAM sumoylation in PC12 cells. (A) Immunostaining of DREAM in UR61 PC12
cells showing its preferred nuclear localization after neuronal differentiation with
dexamethasone. Co-staining with propidium iodide is shown. Scale bar corresponds to
5 μm. (B) Coimmunoprecipitation of endogenous DREAM and SUMO-1 in non-
differentiated and NGF-differentiated PC12 cells. Sumoylated DREAM migrates as a
dimer (upper panel, arrow) and is present in the nuclear and absent in the cytosolic
fraction. *Denotes nonspeciﬁc band. Nonsumoylated DREAM migrates as a monomer
(lower panel, arrow) and is present both in the cytosolic and the nuclear fraction.
(C) Quantiﬁcation of the sumoylated and non-sumoylated DREAM bands shows the
increased accumulation of DREAM in the nuclear fraction in NGF-differentiated PC12
cells.
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non-canonical KxE/D motifs and one canonical YKxE motif. This
represents four times the statistically expected number based on
protein length suggesting that the original yeast two-hybrid obser-
vation corresponds to a functionally relevant interaction between
Ubc9 and DREAM. Instead of analyzing all possible single/multiple
sumoylation mutants, we discarded sumolyation sites considered
unfavorable based on low solvent accessibility. At difference from the
case of calmodulin, in which Ca2+ binding results in a large
conformational change [37], Ca2+-dependent long-range conforma-
tional changes are not expected to occur in neuronal calcium sensors,
including the KChIPs and recoverin [38], among others. Thus, our
assumptions that K184 and K221 are not surface exposed are likely to
be valid for a range of modiﬁed states of DREAM.
Results from the mutational analysis are consistent with that at
least two sites, K26 and K90, are important for sumoylation-
dependent nuclear localization of DREAM, since conservative muta-
tion of either K26 or K90 to arginine is sufﬁcient to inhibit nuclear
translocation/retention. In vitro DREAM sumoylation at K241 is not
directly related to nuclear localization but may nonetheless be
important for modulation of other yet to be characterized DREAMfunctions in the cytosol. The perfect sumoylation consensus site at
K101 is not sumoylated in vitro, and its mutation does not alter the
transcriptional repressor activity of DREAM. Lack of modiﬁcation at
K101 could be due to an unfavorable position within the helix
structure, which would impede Ubc9–target interaction [1]. Sequence
analysis of the four members of the KChIP family shows that the
sumoylation consensus site at K101, in the DREAM sequence, is the
only site conserved in all four, whereas K26, located in the DREAM-
speciﬁc N-terminal region, is not present in the other three members.
The sumoylation site at K90 is conserved in KChIP 1 and 2 but not in
KChIP4, and K241 is absent in KChIP1. Thus, sumoylation of other
KChIP family members may occur and remains to be further
investigated.
It has been proposed that phosphorylation at serine residues
located ﬁve amino acids downstream from the sumoylation site is
associated with increased sumoylation and modiﬁed transcriptional
activity of several nucleoproteins, including HSF1, PPAR-γ and MEF2
[8,39]. We have not determined, however, whether simultaneous
post-translational modiﬁcations are needed or can inﬂuence the
sumoylation of DREAM. A serine residue at position 95, ﬁve amino
acids downstream from the K90 sumoylation site, is present in
DREAM (Fig. 2), while the othermembers of the DREAM/KChIP family,
but not DREAM, have a serine residue at position 106, ﬁve amino acids
downstream from the K101 sumoylation site. GRK2-mediated
phosphorylation at Ser95 in DREAM regulates the intracellular
trafﬁcking of Kv4 potassium channels. Ser-to-Ala mutation of this
residue affects the interaction with the Kv4 potassium channel. This
mutant, however, retains its repressor activity [14], suggesting that
phosphorylation at Ser95 in DREAM is not required for sumoylation
and nuclear translocation. Whether sumoylation also regulates
nuclear translocation of the other KChIP proteins and whether
phosphorylation at Ser106 has a functional role in their potential
sumoylation at K101 has not been characterized in this study.
The coexistence of sumoylated and nonsumoylated DREAM in
PC12 cells suggests that the two forms are in equilibrium with (i)
sumoylation and nuclear import controlled by NGF-induced neuronal
differentiation and (ii) desumoylation and nuclear export of DREAM
controlled by an active, presently unknown, mechanism. The
increased presence of sumoylated DREAM in the nucleus following
neuronal differentiation supports the physiological signiﬁcance of the
sumoylation process in this cell system. Other important aspects that
remain to be analyzed are whether sumoylation alters the interaction
of DREAM with other nucleoproteins and whether sumoylated
DREAM modiﬁes the afﬁnity or the speciﬁcity of the interaction
with DRE sites. Importantly, sumoylated DREAM in PC12 cells is
exclusively nuclear and is present as a multimer, the form with the
highest afﬁnity for DNA and thus with the highest capacity to repress
DRE-dependent transcription.
Neurons involved in sensory processing express high levels of
DREAM [33], and we have found that in sensory neurons from
trigeminal ganglia, the DREAM protein is mostly concentrated in the
nucleus, where double immunohistochemical detection showed that
DREAM colocalizes with SUMO-1 immunoreactivity. Biochemical
analysis, e.g., coimmunoprecipitation of sumoylated DREAM in
trigeminal neurons is hampered by the low availability of biological
sample and the accessibility to reagents for detection in these
conditions. The substantial presence of DREAM in nuclear euchroma-
tin domains in trigeminal neurons indicates an important role for
DREAM in transcriptional control of the processing of sensory
information and makes DREAM and maybe the inhibition of DREAM
sumoylation new targets for the treatment of trigeminal pain.
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